Intuitive Surgical, Inc.
Intuitive Surgical Reports New Employee Option Grants for March 2014
SUNNYVALE, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG) today reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 26 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive Surgical, Inc. 2009 Commencement Incentive Plan, which the Board of Directors of Intuitive Surgical, Inc. adopted for the granting of equity awards to new employees. In accordance with NASDAQ rules, these grants were made under an equity incentive plan without shareholder approval. NASDAQ rules require a public announcement of equity awards to be made under this type of plan. 26 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 3,134 shares of the Company's common stock; 2,389 of the shares granted were Stock Options and 745 of the shares granted were RSUs. Both the RSUs and Stock Options vest over four years. The Stock Options expire in 10 years assuming continued employment. No officers received any award under this plan. The exercise price for the Stock Options granted is $443.98 which was the closing price of Intuitive Surgical, Inc.'s common stock on the NASDAQ Global Market as such price was reported by NASDAQ on March 7, 2014. The Company's policy is to issue RSUs and Stock Option grants to new employees, where equity makes sense, on the fifth business day of every calendar month.
Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections
DURHAM, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. FDA has committed to work expeditiously with Chimerix on the design of a pivotal Phase 3 study that would be a continuation of this pilot study. Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovir's potential in adenovirus infection. This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014.
Seeger Weiss LLP
Jury to Roche: You Failed to Properly Warn Physicians of the Risk of Ulcerative Colitis With Acne Drug Accutane; Roche Ordered to Pay $1.59 Million to Former Accutane User, According to Seeger Weiss LLP
ATLANTIC CITY, N.J., March 11, 2014 (GLOBE NEWSWIRE) -- A jury in New Jersey returned a $1.59 million verdict to a former Accutane user against N.J.-based pharmaceutical companies Hoffmann La-Roche Inc. and Roche Laboratories. The plaintiff, Kamie Kendall Rees, was prescribed several courses of Accutane for treatment of her acne in the 1990s, starting at the age 12. Shortly thereafter, Ms. Kendall Rees developed ulcerative colitis—a permanent, debilitating disease. Unable to manage her disease, Ms. Kendall Rees was later forced to have her colon removed. The trial was a re-trial of a 2008 verdict challenged by Roche to the New Jersey Supreme Court.
BG Medicine Inc.
BG Medicine Compliant With NASDAQ Listing Requirements
WALTHAM, Mass., March 11, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") today announced that it has received correspondence from The NASDAQ Stock Market LLC ("NASDAQ") confirming that the Company has evidenced compliance with the requirements for continued listing on The NASDAQ Capital Market. Accordingly, the NASDAQ compliance matter has been closed.
Nordic Shipholding A/S
Nordic Shipholding A/S - Annual Report 2013
March 11, 2014
NORDIC SHIPHOLDING A/S
Nordic Shipholding A/S – Annual Report 2013
Company Announcement: 4/2014
Published via NASDAQ OMX on March 11, 2014
In 2013, Nordic Shipholding A/S reaped a gain of USD 19.4 million, chiefly from
a one-time USD 28.6 million gain from restructuring. Excluding this gain, the
Group realised a loss of USD 9.1 million.
Nordic Shipholdings’ Board of Directors has today approved the annual report